CompletedNCT03603847
Prospective Study of the Prognostic Value of New Markers in Adults With ALK-positive Large Anaplastic Lymphoma
Studying ALK-negative anaplastic large cell lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- The Lymphoma Academic Research Organisation
- Principal Investigator
- David SIBON, MD, M.DHôpital Necker-Enfants Malades
- Enrollment
- 41 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2018 – 2023
Study locations (15)
- CHU Amiens - Hôpital Sud, Amiens, France
- CHU d'Estaing, Clermont-Ferrand, France
- APHP - Hopital Henri Mondor, Créteil, France
- CHU Grenoble, Grenoble, France
- CHRU de Lille - Hôpital Claude Huriez, Lille, France
- Institut Paoli Calmette, Marseille, France
- APHP - Hôpital Necker, Paris, France
- APHP - Hôpital Saint Louis, Paris, France
- CHU Bordeaux - Centre François Magendie, Pessac, France
- Centre Hospitalier Lyon Sud, Pierre-Bénite, France
- CHU de Rennes - Hôpital de Pontchaillou, Rennes, France
- Centre Henri Becquerel, Rouen, France
- CHRU de Strasbourg, Strasbourg, France
- Institut Universitaire du Cancer de Toulouse - Oncopole, Toulouse, France
- CHU Brabois, Vandœuvre-lès-Nancy, France
Collaborators
Hôpital Necker-Enfants Malades · Fondation ARC · Pfizer · Takeda
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03603847 on ClinicalTrials.govOther trials for ALK-negative anaplastic large cell lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07300514Golidocitinib Versus Placebo as Maintenance Therapy for Peripheral T-Cell LymphomaFudan University
- RECRUITINGPHASE2NCT07356245Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell LymphomaJonathan Brammer
- RECRUITINGPHASE1NCT06176690Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive LymphomasBaylor College of Medicine
- RECRUITINGPHASE1NCT07001384A Study of Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma (ALK+ALCL)Memorial Sloan Kettering Cancer Center
- ACTIVE NOT RECRUITINGPHASE2NCT07013565Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCLNew York Medical College
- RECRUITINGPHASE3NCT06724237Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial ChemotherapyEastern Cooperative Oncology Group
- RECRUITINGPHASE2NCT05996185Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell LymphomaYale University
- RECRUITINGPHASE1NCT06508463Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell LymphomaMayo Clinic
See all trials for ALK-negative anaplastic large cell lymphoma →